Balchem Corporation Completes Acquisition of Kappa
NEW HAMPTON, NY, June 21, 2022 (GLOBE NEWSWIRE) — Balchem Corporation (NASDAQ: BCPC), a global specialty ingredients company focused on nutrition and health, announced today that it has finalized its acquisition of Kappa Bioscience AS, a leading science company. manufacturer of specialty vitamin K2 for the human nutrition industry, headquartered in Oslo, Norway. The signing of a definitive agreement for the acquisition of Kappa Bioscience AS was previously announced on June 14, 2022.
With this acquisition, Balchem is accelerating its strategy to expand its science-based specialty nutrient portfolio with leading positions in growing markets. Vitamin K2 is a fast-growing, specialty vitamin that plays a crucial role in the human body for bone health, heart health, immunity, and athletic performance. Primarily, vitamin K2 supports the transport and distribution of calcium in the body. Vitamin K2 is important at all stages of life, from pregnancy and early life to healthy aging. Kappa K2VITAL® Branded Vitamin K2 is the leading synthetic Vitamin K2 and is backed by strong intellectual property and an extensive clinical research portfolio.
About Balchem Corporation
Balchem Corporation develops, manufactures and markets specialty ingredients that enhance and enhance the health and well-being of life on the planet by providing cutting-edge solutions and the highest quality products for a range of industries in the whole world. The Company reports three business segments: Human Nutrition and Health; animal nutrition and health; and specialty products. The Human Nutrition & Health segment provides customized food and beverage ingredient systems and key nutrients in a variety of applications in the food, supplement and pharmaceutical industries. The Animal Nutrition and Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty packaged chemicals for use in healthcare and other industries, and also supplies chelated minerals to the agricultural micronutrient market.
About Kappa Bioscience
Kappa Bioscience AS was founded in Oslo, Norway in 2006 following a breakthrough discovery: the synthesis of pure and fully bioactive Vitamin K2 MK-7, an essential vitamin needed to direct calcium in our body and maintain heart, bones and many other healthy things. Today, this pioneering spirit is still going strong. With patented processes, innovative technology and recognized expertise, Kappa Bioscience AS produces K2VITAL® and K2VITAL® Delta; vitamin K2 with unparalleled purity and stability, in a wider range of formulations than anyone else, to bring the best possible vitamin K2 benefits to everyone.
From vitamin K2 and turnkey solutions to research and marketing initiatives, product launches and growth strategies, Kappa Bioscience AS believes in getting it right. It means developing products and services that set new standards of excellence, made with integrity and through close collaboration. In collaboration with its partners, Kappa Bioscience AS helps the health and nutrition industry to reach a milestone, without cutting corners.
This release contains forward-looking statements, which reflect Balchem’s expectations or beliefs regarding future events that involve risks and uncertainties. Balchem cannot guarantee that the expectations reflected in the forward-looking statements will prove to be accurate and a variety of factors could cause actual results to differ materially from Balchem’s expectations, including the risks and factors identified in Balchem’s annual report on Form 10-K for the year ended December 31. , 2021. Forward-looking statements are qualified in their entirety by the above cautionary statement. Balchem undertakes no obligation to update its outlook or other forward-looking statements as of any future date.
Jacqueline Yarmolowicz, Executive Assistant
Email: [email protected]